A Phase II/III Study of N-803 ALT-803 plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy Lung-MAP Non-Match Sub-Study

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
II/III

ClinicalTrials.gov Identifier:
NCT05096663

Study #:
STUDY00148498

Start Date:
Mar 21, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05096663

View Complete Trial Details & Eligibility at ClinicalTrials.gov